Show simple item record

AuthorCampbell, Jessica
AuthorSutherland, Juliet
AuthorBucknall, Danielle
AuthorO’hara, Lily
AuthorHeywood, Anita
AuthorHobbs, Matthew
AuthorBallantyne, Angela
AuthorGray, Lesley
Available date2022-08-22T07:05:24Z
Publication Date2021-12-01
Publication NameVaccines
Identifierhttp://dx.doi.org/10.3390/vaccines9121466
CitationCampbell, J.; Sutherland, J.; Bucknall, D.; O’Hara, L.; Heywood, A.; Hobbs, M.; Ballantyne, A.; Gray, L. Equity in Vaccine Trials for Higher Weight People? A Rapid Review of Weight-Related Inclusion and Exclusion Criteria for COVID-19 Clinical Trials. Vaccines 2021, 9, 1466. https://doi.org/10.3390/vaccines9121466
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85121537691&origin=inward
URIhttp://hdl.handle.net/10576/33325
AbstractHigher weight status, defined as body mass index (BMI) ≥ 30 kg/m2, is frequently described as a risk factor for severity and susceptibility to severe acute respiratory syndrome coron-avirus 2 (SARS-CoV-2) disease (known as COVID-19). Therefore, study groups in COVID-19 vaccine trials should be representative of the weight spectrum across the global population. Appropriate subgroup analysis should be conducted to ensure equitable vaccine outcomes for higher weight people. In this study, inclusion and exclusion criteria of registered clinical trial protocols were reviewed to determine the proportion of trials including higher weight people, and the proportion of trials conducting subgroup analyses of efficacy by BMI. Eligibility criteria of 249 trial protocols (phase I, II, III and IV) were analysed; 51 protocols (20.5%) specified inclusion of BMI > 30, 73 (29.3%) specified exclusion of BMI > 30, and 125 (50.2%) did not specify whether BMI was an inclusion or exclusion criterion, or if BMI was included in any ‘health’ screenings or physical examinations during recruitment. Of the 58 protocols for trials in phase III and IV, only 2 (3.4%) indicated an intention to report subgroup analysis of vaccine efficacy by weight status. Higher weight people appear to be significantly under-represented in the majority of vaccine trials. This may result in reduced efficacy and acceptance of COVID-19 vaccines for higher weight people and exacerbation of health inequities within this population group. Explicit inclusion of higher weight people in COVID-19 vaccine trials is required to reduce health inequities.
Languageen
PublisherMDPI
SubjectBMI
Clinical trial
COVID-19
Equity
Higher weight
Inequity
Vaccination
Vaccine
TitleEquity in vaccine trials for higher weight people? A rapid review of weight-related inclusion and exclusion criteria for COVID-19 clinical trials
TypeArticle
Issue Number12
Volume Number9
ESSN2076-393X
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record